Star Combo Pharma (ASX:S66) ROCE %: 2.44% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:S66 Star Combo Pharma Ltd ASX:S66
35 GF Score
Price A$0.13
GF Value A$0.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Star Combo Pharma ROCE %?

Star Combo Pharma ASX:S66 35 ROCE % is 2.44% as of Dec. 2025. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Star Combo Pharma's annualized ROCE % for the quarter that ended in Dec. 2025 was 2.44%.

Star Combo Pharma  (ASX:S66) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Star Combo Pharma ROCE % Related Terms

Star Combo Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for Star Combo Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Star Combo Pharma ROCE % Chart

Star Combo Pharma Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only -14.33 -1.99 -8.45 3.17 13.71

Star Combo Pharma Semi-Annual Data
Jun17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.61 4.70 2.01 25.38 2.44
ASX:S66
35GF Score
Star Combo Pharma Ltd ASX:S66
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Star Combo Pharma ROCE % Calculation

Star Combo Pharma's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=5.505/( ( (42.597 - 4.872) + (48.451 - 5.861) )/ 2 )
=5.505/( (37.725+42.59)/ 2 )
=5.505/40.1575
=13.71 %

Star Combo Pharma's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=1.048/( ( (48.451 - 5.861) + (46.987 - 3.695) )/ 2 )
=1.048/( ( 42.59 + 43.292 )/ 2 )
=1.048/42.941
=2.44 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 2.44% mean?
Star Combo Pharma (ASX:S66) has a ROCE % of 2.44% as of Dec. 2025.
Is Star Combo Pharma's ROCE % too high?
Star Combo Pharma's current ROCE % is 2.44%. The Consumer Packaged Goods industry median ROCE % is 8.89. Star Combo Pharma's value of 2.44% is 72.5% below this industry median. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's ROCE % compare to PG and CL?
Star Combo Pharma's ROCE % of 2.44% can be compared against companies in the Consumer Packaged Goods industry. The industry median ROCE % is 8.89. Star Combo Pharma's value of 2.44% is 72.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Consumer Packaged Goods company?
The median ROCE % among Consumer Packaged Goods companies is 8.89, based on 1,942 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current ROCE % of 2.44% is 72.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median ROCE % is 8.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current ROCE % is 2.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current ROCE % is 2.44% and 72.5% below the Consumer Packaged Goods industry median of 8.89. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current ROCE % is 2.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Star Combo Pharma (ASX:S66) Overvalued in 2026?

Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued. The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13. GuruFocus considers Star Combo Pharma to be Fairly Valued.

Key valuation signals for ASX:S66:

  • ROCE %: 2.44%
  • GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
  • GF Score™: 35/100 with 2 warning signs
  • Industry Position: 72.5% below the Consumer Packaged Goods median

No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Star Combo Pharma Business Description

Address 171 - 177 Woodpark Road, Smithfield, Sydney, NSW, AUS, 2164
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score

Get the complete analysis for ASX:S66

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.13
GF Value